Zealand Pharma A/S (CPH:ZEAL)

Denmark flag Denmark · Delayed Price · Currency is DKK
368.60
-6.10 (-1.63%)
Jun 23, 2025, 5:50 PM CET
-51.97%
Market Cap 26.17B
Revenue (ttm) 55.69M
Net Income (ttm) -1.19B
Shares Out 70.99M
EPS (ttm) -17.26
PE Ratio n/a
Forward PE 4.81
Dividend n/a
Ex-Dividend Date n/a
Volume 480,973
Average Volume 786,894
Open 369.80
Previous Close 374.70
Day's Range 364.60 - 376.00
52-Week Range 365.10 - 972.00
Beta 0.56
RSI 34.03
Earnings Date Aug 14, 2025

About Zealand Pharma

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 335
Stock Exchange Copenhagen Stock Exchange
Ticker Symbol ZEAL
Full Company Profile

Financial Performance

In 2024, Zealand Pharma's revenue was 62.69 million, a decrease of -81.71% compared to the previous year's 342.79 million. Losses were -1.08 billion, 53.3% more than in 2023.

Financial Statements

News

Zealand Pharma Obesity Therapy Shows Positive Trial Results

Zealand Pharma said its obesity treatment dapiglutide showed positive topline results in its latest trial, demonstrating its further potential for weight loss and to treat obesity-related comorbiditie...

5 days ago - Market Watch

Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

Company announcement – No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a mean o...

5 days ago - GlobeNewsWire

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S (“Zealand Pharma...

17 days ago - GlobeNewsWire

Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome

Press release – No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Copenhagen, Denmark, June 2, 2025 – Z...

22 days ago - GlobeNewsWire

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Company announcement – No. 13 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhag...

27 days ago - GlobeNewsWire

European stocks edge higher after Trump delays 50% tariffs on EU

European shares traded in positive territory on Monday.

4 weeks ago - CNBC

European stocks recover after Trump delays EU tariffs in hopes of deal

European shares kicked off the week on a positive note on Monday, recouping the previous session's losses, as markets heaved a sigh of relief after U.S. President Donald Trump delayed his threat to im...

4 weeks ago - Reuters

Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer

Press release – No. 9 / 2025 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer...

5 weeks ago - GlobeNewsWire

Zealand: Promising Roche-Partnered Obesity Drug Developer - But Stock Is Pricey

Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF market potential and challenges.

5 weeks ago - Seeking Alpha

Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025

Press release – No. 8 / 2025 Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025 Copenhagen, Denmark, May 12, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-n...

6 weeks ago - GlobeNewsWire

Zealand Pharma A/S (ZLDPF) Q1 2025 Earnings Call Transcript

Zealand Pharma A/S (OTCPK:ZLDPF) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ETCompany ParticipantsAdam Lange - Vice President, Investor...

6 weeks ago - Seeking Alpha

Zealand Pharma announces closing of collaboration and license agreement with Roche

Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or “Zealand...

6 weeks ago - GlobeNewsWire

Zealand Pharma Announces Financial Results for the First Three Months of 2025

Company announcement – No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capabi...

6 weeks ago - GlobeNewsWire

Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit

The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion dealto develop Danish biotechZealand Pharma's "next generation" weight loss drug.

7 weeks ago - CNBC

Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results

Press Release – No. 7 / 2025 Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results Copenhagen, Denmark, May 1, 2025 – Zealand Pharma A/S (Nasdaq C...

7 weeks ago - GlobeNewsWire

Zealand Pharma says obesity drug deal with Roche will help it stay independent

Danish biotech is developing petrelintide in partnership with the Swiss pharma group

2 months ago - Financial Times

Zealand Pharma begins mid-stage trial for obesity drug candidate in people with type 2 diabetes

Danish biotechnology company Zealand Pharma said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss drug candidate petrelintide in people with overweight or obesit...

2 months ago - Reuters

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes

Press release – No. 6 / 2025 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes The Phase 2b ZUPRE...

2 months ago - GlobeNewsWire

Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery

Press release – No. 5 / 2025 Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal joins Zealand Pharma at a pivotal moment as i...

2 months ago - GlobeNewsWire

Zealand Pharma (ZLDPF) Launches 2025 Incentive Program | ZLDPF Stock News

Zealand Pharma (ZLDPF) Launches 2025 Incentive Program | ZLDPF Stock News

2 months ago - GuruFocus

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Company announcement – No. 10 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhag...

2 months ago - GlobeNewsWire

Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2025

Company announcement – No. 9 / 2025 Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2025 Copenhagen, Denmark, April...

2 months ago - GlobeNewsWire

Zealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With Roche

The Danish biotech's recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed its potential.

2 months ago - WSJ